Corteva, Inc. (CTVA Quick QuoteCTVA - Free Report) executives focused the third-quarter 2026 earnings call on worsening conditions in Brazil, which prompted a significant reduction in full-year profitability expectations despite resilient performance elsewhere.

The company reported adjusted earnings of 6 cents per share, missing the Zacks Consensus Estimate of 9 cents.

Revenues of $1.52 billion also fell short of the $1.77 billion consensus. Management emphasized inventory imbalances, pricing pressure and cost reductions as critical priorities.

Corteva, Inc. Price, Consensus and EPS Surprise

Corteva, Inc. price-consensus-eps-surprise-chart | Corteva, Inc. Quote

CTVA Cuts Outlook Amid Brazil Weakness

Chief financial officer Jeffrey Rudolph lowered the 2026 adjusted pro forma operating EBITDA outlook to $1.1-$1.13 billion from approximately $1.3 billion projected at September's Investor Day.

The revised outlook reflects weaker pricing, reduced volumes and persistent inventory challenges in Brazil. Fourth-quarter EBITDA is expected to be approximately half the prior-year level.

Full-year operating earnings are projected at 76-80 cents per share. Rudolph attributed the guidance reduction entirely to Brazil, with approximately $100 million of the EBITDA impact tied to elevated channel inventories.

Corteva Confronts Inventory and Pricing Challenges

CEO Luther Kissam acknowledged that Corteva entered the Brazilian growing season with approximately $250 million of excess channel inventory, measured by associated revenue, carried over from 2025.

During questioning from Vertical Research Partners, Kissam explained that management would not extend additional credit to overdue distributors or redirect inventory into other markets merely to support sales.

Latin American organic sales declined 31%, reflecting a 24% volume contraction and 7% pricing decline. Kissam expects inventories to normalize by the end of Brazil's current growing season.

CTVA Sees Differentiated Products Supporting Demand

Outside Latin America, operating trends remained resilient. North America delivered 7% organic growth, while EMEA and Asia Pacific recorded increases of 14% and 5%, respectively.

Kissam highlighted 20% quarterly volume growth from new products across all regions. Arylex and Pyraxalt each registered volume increases exceeding 20%, reinforcing management's innovation strategy.

However, mature-product pricing remained challenging. Rudolph identified approximately $120 million in quarterly pricing headwinds, primarily from U.S. acetochlor and Brazilian generic competition.

Corteva Targets Structural Cost Reductions

Kissam outlined an expanding efficiency program involving manufacturing, logistics, commercial infrastructure and administrative processes. A third-party review of the company's cost structure has commenced.

During questioning from BMO Capital Markets, management indicated that its review includes potential product exits, alternative distribution arrangements and reductions in organizational complexity.

A hiring freeze and tighter discretionary spending controls are already underway. Kissam expects the broader transformation to extend over four to eight quarters, with technology and automation contributing to efficiencies.

CTVA Addresses 2027 Recovery and Capital Priorities

During questioning from UBS, Kissam expressed confidence in returning to growth in 2027, supported by inventory normalization, new products and additional cost actions.

Rudolph noted selective stabilization in generic chemical pricing, although Brazil remains uncertain. Acetochlor-related pricing headwinds should diminish through the first half of 2027.

Management also reaffirmed its approximately $1.5 billion year-end cash target. Kissam identified share repurchases as a 2027 priority, while separation-related restrictions prevent fourth-quarter buybacks.

Corteva Faces Strategic Decisions in Brazil

During questioning from BofA Securities, Kissam acknowledged that Brazil's long-term operating model requires reassessment, including its commercial footprint, distribution strategy and profitability.

Management is evaluating whether existing infrastructure adequately supports returns, while considering how reduced Brazilian volumes could affect manufacturing economics elsewhere.

The broader message remained focused on preserving differentiated product growth while correcting inventory imbalances and reducing costs. Management intends to provide further details on restructuring and 2027 expectations during February's earnings call.

CTVA's Zacks Rank and Style Scores Signal Caution

CTVA currently carries a Zacks Rank #5 (Strong Sell), reflecting an unfavorable earnings estimate revision outlook. Its Value Score of B indicates relatively attractive valuation characteristics, while its Momentum Score of B points to favorable price momentum characteristics. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

However, the Growth Score of F reflects weak growth characteristics, while the composite VGM Score of D indicates an unfavorable overall combination of value, growth and momentum factors.

The combination of a Zacks Rank #5 and weak composite Style Score points to an unfavorable near-term outlook under the Zacks framework. The Zacks Rank can change as analysts revise earnings estimates following the recently reported results.